WLF to DOJ: clean up prosecution of drug promotion

Share this article:
The Washington Legal Foundation (WLF) called for the U.S. Department of Justice to rein in the Office of Consumer Litigation, which supervises cases involving alleged improper promotion by pharmaceutical firms and medical device manufacturers.
In a letter to deputy attorney general James Comey, the free-market think tank called on the Department of Justice to reassign oversight for cases involving drug promotion to its Criminal Division, which, the WLF said, "has far more expertise in addressing the sensitive issues inherent in any criminal investigation."
The WLF said that the OCL has failed to set clear standards regarding what forms of promotional activities are prosecutable.
"To date, OCL has failed to provide clear guidance and coordination," said the letter. "Indeed, OCL has left senior FDA officials largely in the dark regarding criminal investigations that it has approved."
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...